Company Profile
Biofrontera Inc Stock Price, News & Analysis
- Ticker:
- BFRI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.25 USD (+0.81%)
Close
Last updated: August 6, 2026
13.2M USD
Market cap
Why the stock is moving
The latest company update was “Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026”. BFRI changed 0.81% and closed at $1.25 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Dermatology Photodynamic Therapy
Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States. Its principal platform combines Ameluz, a topical photosensitizer, with the RhodoLED illumination system.
Actinic Keratosis Franchise
Ameluz is established in actinic keratosis and is being developed for broader treatment fields and additional body locations. The company is also pursuing superficial basal cell carcinoma and acne to expand the platform.
U.S. Commercial Infrastructure
Biofrontera operates a specialist dermatology sales organization and has restructured its economics with Biofrontera AG to retain a larger share of product value.
Future catalysts
The FDA assigned September 28, 2026, as the PDUFA action date for the Ameluz supplemental NDA in superficial basal cell carcinoma.
Phase 3 results in actinic keratoses on the extremities, neck, and trunk are expected to support a future label-expansion filing.
Recent news
- 01
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
Source: Biofrontera Inc
- 02
- 03
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Source: Biofrontera Inc
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Biofrontera Inc (BFRI)?
Biofrontera Inc (BFRI) most recently closed at 1.25 USD, a +0.81% move versus the previous session.
What is the market cap of Biofrontera Inc (BFRI)?
Biofrontera Inc currently has a market capitalization of 13.2M USD on BioPharmSignal.
What does Biofrontera Inc do?
Dermatology Photodynamic Therapy Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States. Its principal platform combines Ameluz, a topical photosensitizer, with the RhodoLED illumination system. Actinic Keratosis Franchise Ameluz is established in actinic keratosis and is being developed for broader treatment...
On which exchange is BFRI stock listed?
Biofrontera Inc (BFRI) is associated with NASDAQ, United States, Biopharma.
What is Dermatology?
Dermatology Photodynamic Therapy Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States.
Which conditions is Biofrontera Inc targeting with Dermatology?
Biofrontera Inc is associated with dermatology based on its company overview and current catalyst commentary.
How does Biofrontera Inc describe recent progress with Dermatology?
The FDA assigned September 28, 2026, as the PDUFA action date for the Ameluz supplemental NDA in superficial basal cell carcinoma. Phase 3 results in actinic keratoses on the extremities, neck, and trunk are expected to support a future label-expansion filing.
What is Photodynamic?
Dermatology Photodynamic Therapy Biofrontera commercializes photodynamic therapy products for dermatologic disease in the United States.